Moody Aldrich Partners LLC Neurocrine Biosciences Inc Transaction History

Moody Aldrich Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$94.02 - $117.1 $457,219 - $569,457	4,863 New	4,863 $547,000
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $161,837 - $227,457	-1,683 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$85.09 - $130.36 $143,206 - $219,395	1,683 New	1,683 $205,000
Q4 2018 Feb 12, 2019	SELL	$68.32 - $124.36 $117,851 - $214,521	-1,725 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$98.88 - $125.85 $170,568 - $217,091	1,725 New	1,725 $212,000
Q1 2018 Apr 26, 2018	SELL	$75.88 - $92.43 $205,027 - $249,745	-2,702 Closed	0 $0
Q4 2017 Jan 31, 2018	SELL	$58.53 - $77.59 $1.14 Million - $1.52 Million	-19,554 Reduced 87.86%	2,702 $210,000
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $1.07 Million - $1.36 Million	22,256	22,256 $1.36 Million

650

96.2M

380K

382K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Aldrich Partners LLC with notifications on news.